SOURCE: BioMedReports

BioMedReports

March 30, 2011 13:38 ET

Report: Mendacious Articles Against Radient Pharmaceuticals Taking Toll on Tabloid's Credibility

LOS ANGELES, CA--(Marketwire - March 30, 2011) - A special report updating investors about Radient Pharmaceuticals' (NYSE Amex: RPC) upcoming clinical validation study and questioning the accuracy of numerous articles published by a senior columnist on behalf of TheStreet.Com is now available at:

http://biomedreports.com/2011033065533/what-motivates-the-mendacious-articles-against-radient-pharmaceuticals.html

Biotech investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556